Randomization began after treatment had started
STEP 4 first gave 902 adults semaglutide during a 20-week run-in. The 803 participants who reached the specified maintenance dose were then randomized to continue semaglutide or switch to placebo for 48 weeks. Both groups continued a lifestyle intervention. Participants did not have diabetes. [1]
This is a maintenance experiment with a selected starting population. It asks about the next phase for people who reached randomization, rather than the average experience of everyone first offered a prescription. That distinction becomes especially important if a headline uses this trial to describe the likelihood of tolerating treatment from day one.
Read the second phase from its own baseline
Before randomization, participants had lost an average 10.6% of body weight. From week 20 to week 68, average change was a further −7.9% with continued semaglutide and +6.9% after switching to placebo. Gastrointestinal events during the randomized period occurred in 49.1% and 26.1%, respectively. [1]
The second-phase percentages use weight at randomization as their reference. They should not simply be added to or subtracted from the initial percentage as though the denominator were unchanged. When reading a withdrawal chart, identify the point at which treatment groups separate before interpreting the size of the subsequent change.
The question answered—and those left open
The design supports a conclusion about continuation compared with withdrawal under these conditions. It does not compare tapering strategies, different maintenance doses, intermittent treatment, a provider transfer or a change to another medicine. Each would require a different comparison. None can be inferred just because its practical goal is also maintenance.
Nor does the group average establish that every participant regained weight or that every individual needs an identical future plan. The useful interpretation is that stopping the studied treatment and continuing it produced different average trajectories. The individual interpretation belongs in a conversation that includes benefit, tolerability and the reason a change is being considered.
A withdrawal study also illustrates why continuing eligibility matters. People who do not reach randomization are part of the starting-treatment experience even when they are absent from the later comparison. Keep that earlier phase in view when reading a reassuring maintenance safety percentage.
Make maintenance a concrete conversation
Before committing to a short introductory membership, ask how the service handles ongoing monitoring and what happens after an initial goal is reached. Establish who reviews treatment interruptions and who can answer a question between scheduled visits. Administrative availability should be confirmed before it becomes urgent.
Our maintenance-conversation guide turns those issues into questions. For a move between clinics, use the separate switching checklist. STEP 4 informs the clinical importance of continuity; it does not supply instructions for timing a transfer or changing treatment yourself.